Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Clover Health: Will Volatility Bring Another Short Squeeze?

Stock MarketsSep 19, 2021 11:31AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Clover Health: Will Volatility Bring Another Short Squeeze?

Clover Health (CLOV) stock has witnessed significant volatility in 2021 thus far. The stock touched its 52-week high of $28.85 a share in June. However, Clover Health since sold off impressively to close around $8 per share mid-week.

These sorts of volatile swings appear to be indicative of the speculative nature of the market right now. Indeed, CLOV stock remains one of the most speculative of its peer group. The retail investor interest with this stock remains sky-high, fueling some otherwise wild swings many other stocks don't typically see.

This is a stock that many investors point to as a short squeeze candidate. Why? Well, the stock squeezed more than 200% in early September in the matter of approximately one week. That is, before shares fell back to earth.

Will this stock go on another run again? Or will investors see more pain on the horizon? Right now, I remain on the fence with this stock.

(See Clover Health stock charts on TipRanks)

CLOV Stock could do it Again

There are certainly quite a few investors out there who remain bullish on Clover Health's ability to squeeze once again. Indeed, relatively high short interest and borrow fee rates that are higher than average have made it so.

Of course, just because a stock is heavily shorted or unfavored doesn't mean it will do well. Quite the opposite, actually. Typically, the markets provide a rather impeccable pricing mechanism. Sometimes the market gets things wrong. However, over the long-term, we see that the stock market is a pretty good estimator of value for companies.

That said, insiders and institutions own approximately 74% of Clover Health's float. This means that if everyone sticks together and holds on with diamond hands, anything's possible.

Indeed, institutional money is often referred to as "smart money" in the markets. The fact that such a large chunk of CLOV stock is held by institutions suggests this is a company some rather smart individuals believe in.

Therefore, investors enthusiastic about another surge in CLOV stock should trade responsibly. 

Mixed Quarterly Results 

Complicating matters for investors bullish on the ability of Clover Health to squeeze is the company's financial results. This past quarter, Clover Health posted revenue growth of 140%, driven mostly by impressive performance in Medicare Advantage premiums and direct contracting revenues.

That said, Clover Health did miss on the bottom line, posting an operating loss of $0.45 per share, versus the $0.17 expected by analysts. In this market, it's perhaps unsurprising to note that CLOV stock surged on these numbers, with the focus clearly being on the company's top line.

Membership growth of more than 125% on a year-over-year basis drove these gains. Adjusted for the net effect of COVID-19, these numbers were still very strong. This indicates there could be additional avenues for further growth down the line.

Clover Health's management team issued strong guidance, for revenues coming in between $1.4 - $1.5 billion. The company expects to lose between $210 million and $250 million on these revenues.

Even with increasing membership and revenue, the company is consistently losing money. That said, there appears to be sufficient appetite for such companies right now. The extent to which the market will continue to reward revenue growth over profitability, however, remains uncertain.

Problematic Business Plan Might be a Hurdle

Clover Health aims to offer vast medical coverage at an affordable rate, compared to its competitors. To do so, the company has to reimburse healthcare service providers faster to help them reduce the cost of providing care. Moreover, Clover Health has outlined plans to potentially pay providers twice that of the industry standard.

Such a business model can't be profitable up front. Investors know that (or should know that). However, Clover Health's plan is to use the Clover Assistant platform to accomplish its business objectives. Clover Assistant is a software that provides technological solutions to cost-cutting objectives. Via technological innovation, Clover Health believes it can lower its cost profile enough to make these investments make sense.

That said, this model isn't yet proven, from a profitability standpoint. The company is growing fast, and is good for consumers. However, investors concerned about the long-term viability of this business model may have reasons to worry, given these ballooning losses every quarter.

What are the Analysts Saying about CLOV?

As per TipRanks' analyst rating consensus, CLOV stock is a Moderate Sell. Out of 4 analyst ratings, there are 1 Hold recommendation and 3 Sell recommendations.

The average Clover Health Investments price target is $9. Analyst price targets range from a low of $7 per share to a high of $10 per share.

Bottom Line

As of now, there isn’t any compelling reason to buy or hold this stock. Sure, CLOV stock could see a nice squeeze at some point in the near future. However, longer-term investors may want to be patient with this company until its business model is proven.

Disclosure: At the time of publication, Chris MacDonald did not have a position in any of the securities mentioned in this article.

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

Clover Health: Will Volatility Bring Another Short Squeeze?

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email